From Self-sufficiency
Jump to: navigation, search
Systematic (IUPAC) name
10-chloro- 11b-(2-chlorophenyl)- 3-methyl- 2,3,7,11b-tetrahydro [1,3]oxazolo [3,2-d] [1,4]benzodiazepin- 6(5H)-one
Clinical data
  •  ?
Routes of
Legal status
Legal status
Pharmacokinetic data
Bioavailability ?
Metabolism Hepatic
Biological half-life ?
Excretion Renal
ATC code none
PubChem CID 4177
Synonyms 13-chloro- 2-(2-chlorophenyl)- 5-methyl- 3-oxa- 6,9-diazatricyclo[,6] tetradeca- 1(10),11,13-trien- 8-one
Chemical data
Formula C18H16Cl2N2O2
Molar mass 363.237 g/mol[[Script error: No such module "String".]]
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Mexazolam (marketed under brand name Melex and Sedoxil)[1] is a drug which is a benzodiazepine derivative.[2] Atorvastatin administration along with mexazolam results in a reduced elimination rate of mexazolam.[3] Mexazolam has been trialed for anxiety and was found to be effective in alleviating anxiety at one week follow-up, however, after three weeks of therapy mexazolam had lost its therapeutic anxiolytic properties becoming no more effective than placebo, presumably due to benzodiazepine tolerance.[4] Mexazolam is metabolised via thee CYP3A4 pathway. HMG-CoA reductase inhibitors including simvastatin, simvastatin acid, lovastatin, fluvastatin, atorvastatin and cerivastatin inhibit the metabolism of mexazolam. Pravastatin, an HMG-CoA reductase inhibitor however, does not inhibit mexazolam metabolism.[5][6]

See also


Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

ja:メキサゾラム pt:Mexazolam
  1. "Benzodiazepine Names". Retrieved 2009-04-05. 
  2. Kurono, Y; Kamiya, K; Kuwayama, T; Jinno, Y; Yashiro, T; Ikeda, K (1987). "Kinetics and mechanism of the acid-base equilibrium of mexazolam and comparison with those of other commercial benzodiazepinooxazole drugs". Chemical & pharmaceutical bulletin. 35 (9): 3831–7. PMID 2893667. 
  3. Mc Donnell, CG; Harte, S; O'driscoll, J; O'loughlin, C; Van Pelt, FN; Shorten, GD (2003). "The effects of concurrent atorvastatin therapy on the pharmacokinetics of intravenous midazolam". Anaesthesia. 58 (9): 899–904. doi:10.1046/j.1365-2044.2003.03339.x. PMID 12911366. 
  4. Ferreira, L; Figueira, ML; Bessa-Peixoto, A; Marieiro, A; Albuquerque, R; Paz, C; Cerqueira, A; Damião, P; Dolgner, A (2003). "Psychomotor and anxiolytic effects of mexazolam in patients with generalised anxiety disorder". Clinical drug investigation. 23 (4): 235–43. doi:10.2165/00044011-200323040-00003. PMID 17535036. 
  5. Ishigami, M; Takasaki, W; Ikeda, T; Komai, T; Ito, K; Sugiyama, Y (2002). "Sex difference in inhibition of in vitro mexazolam metabolism by various 3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors in rat liver microsomes". Drug metabolism and disposition: the biological fate of chemicals. 30 (8): 904–10. doi:10.1124/dmd.30.8.904. PMID 12124308. 
  6. Ishigami, Michi; Honda, Tomoyo; Takasaki, Wataru; Ikeda, Toshihiko; Komai, Toru; Ito, Kiyomi; Sugiyama, Yuichi (2001). "A Comparison of the Effects of 3-Hydroxy-3-Methylglutaryl-Coenzyme A (HMG-CoA) Reductase Inhibitors on the CYP3A4-Dependent Oxidation of Mexazolam in Vitro". Drug Metabolism and Disposition. 29 (3): 282. PMID 11181496.